Learn more about whether Nurix Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The RSUs vest over four years, with 25% of the sharesvesting on each anniversary of the grant date, subject to the new employee's continued service relationship with Travere through the applicable ...

Ligand Pharma (LGND) stock gains as Citi rates the company a Buy, highlighting its underappreciated value despite its strong ...

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Haivision Systems Inc. ("Haivision") , a leading global provider of mission critical, real-time video networking and visual collaboration solutions, plans to announce financial results for its fourth ...

Microbix Biosystems Inc. , a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news ...

Despite decent performance, Armistice Capital plans to give clients shares in a new investment vehicle in lieu of cash for the fourth time in two years.

Citi initiated coverage of Ligand (LGND) with a Buy rating and $270 price target. The firm says the company’s focus on royalties and platform ...

Finerenone use for 6 months was safe and associated with a significant 25% decrease in albuminuria for adults with type 1 diabetes and chronic kidney disease, according to data presented in the ...